LYMPHOMA, T-CELL
Clinical trials for LYMPHOMA, T-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat T-Cell lymphoma: experimental therapy MB-105 enters phase 2
Disease control Recruiting nowThis study tests an experimental drug called MB-105 in people with a type of T-cell lymphoma that has returned or not responded to standard treatments. About 46 adults will receive the drug to see if it shrinks tumors and how safe it is. The goal is to find a better option for th…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated Jun 17, 2026 04:28 UTC
-
New hope for tough lymphomas: experimental drug STP938 enters human trials
Disease control Recruiting nowThis study tests a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least two prior treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The trial has two parts: first, finding the right dose, a…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 17, 2026 04:28 UTC
-
New hope for rare blood cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 17, 2026 04:24 UTC
-
New hope for rare blood cancer: phase 3 trial of soquelitinib launches
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with certain types of T-cell lymphoma that have come back or not responded to therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standard single-agent treat…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New drug may keep T-Cell lymphoma at bay after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent the lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body. A…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 12, 2026 12:16 UTC